Table 1 Characteristic, all, BRCA1, BRCA2, PALB2, stratified by patients. EBC early breast cancer, ABC advanced breast cancer, HR hormone receptor, HER2 human epidermal growth factor receptor 2; TNBC triple-negative breast cancer, OC: ovarian cancer
| Â | Gene status | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Not mutated | Mutated | p Value | BRCA1 (−) | BRCA1 (+) | p Value | BRCA2 (−) | BRCA2 (+) | p Value | PALB2 (−) | PALB2 (+) | p Value | |||||||||||||||||||||||||||||
N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | |||||||||||||||||||||||||
Total (N = 879) | 749 | 85.2% | 130 | 14.8% | – | 852 | 96.9% | 27 | 3.1% | – | 803 | 91.4% | 76 | 8.6% | – | 833 | 94.8% | 46 | 5.2% | – | ||||||||||||||||||||
Group | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||||||||||||||||||||
 Retro | 48 | 87.3% | 7 | 12.7% | 0.069 | 53 | 96.4% | 2 | 3.6% | 0.002 | 50 | 90.9 | 5 | 9.1% | 0.454 | 51 | 92.7% | 4 | 7.3% | 0.604 | ||||||||||||||||||||
 Group 1A | 506 | 87.5% | 72 | 12.5% |  | 569 | 98.4% | 9 | 1.6% |  | 535 | 92.6% | 43 | 7.4% |  | 533 | 95.7% | 25 | 4.3% |  | ||||||||||||||||||||
 Group 1B | 18 | 81.8% | 4 | 18.2% |  | 21 | 95.5% | 1 | 4.5% |  | 19 | 86.4% | 3 | 13.6% |  | 21 | 95.5% | 1 | 4.5% |  | ||||||||||||||||||||
 Group 2 | 91 | 77.8% | 26 | 22.2% |  | 111 | 94.9% | 6 | 5.1% |  | 102 | 87.2% | 15 | 12.8% |  | 109 | 93.2% | 8 | 6.8% |  | ||||||||||||||||||||
 Group 3–1 | 33 | 82.5% | 7 | 17.5% |  | 38 | 95.0% | 2 | 5.0% |  | 37 | 92.5% | 3 | 7.5% |  | 36 | 90.0% | 4 | 10.0% |  | ||||||||||||||||||||
 Group 3–2 | 53 | 79.1% | 14 | 20.9% |  | 60 | 89.6% | 7 | 10.4% |  | 60 | 89.6% | 7 | 10.4% |  | 63 | 94.0% | 4 | 6.0% |  | ||||||||||||||||||||
Stage | ||||||||||||||||||||||||||||||||||||||||
 EBC | 597 | 85.9% | 98 | 14.1% | 0.264 | 680 | 97.8% | 15 | 2.2% | 0.002 | 637 | 91.7% | 58 | 8.3% | 0.537 | 662 | 95.3% | 33 | 4.7% | 0.475 | ||||||||||||||||||||
 ABC | 152 | 82.6% | 32 | 17.4% |  | 172 | 93.5% | 12 | 6.5% |  | 166 | 90.2% | 18 | 9.8% |  | 171 | 92.9% | 13 | 7.1% |  | ||||||||||||||||||||
Subtype | ||||||||||||||||||||||||||||||||||||||||
 HR+/HER2− | 482 | 85.2% | 84 | 14.8% | 0.713 | 553 | 97.7% | 13 | 2.3% | 0.090 | 515 | 91.0% | 51 | 9.0% | 0.921 | 536 | 94.7% | 30 | 5.3% | 0.934 | ||||||||||||||||||||
 HR+/HER2+ | 78 | 85.7% | 13 | 14.3% |  | 88 | 96.7% | 3 | 3.3% |  | 82 | 90.1% | 9 | 9.9% |  | 87 | 95.6% | 4 | 4.4% |  | ||||||||||||||||||||
 HR−/HER2+ | 67 | 88.2% | 9 | 11.8% |  | 74 | 97.4% | 2 | 2.6% |  | 70 | 92.1% | 6 | 7.9% |  | 73 | 96.1% | 3 | 3.9% |  | ||||||||||||||||||||
 TNBC | 108 | 82.4% | 23 | 17.6% |  | 122 | 93.1% | 9 | 6.9% |  | 122 | 93.1% | 9 | 6.9% |  | 122 | 93.1% | 9 | 6.9% |  | ||||||||||||||||||||
 No data | 14 | 93.3% | 1 | 6.7% |  | 15 | 100% | 0 | 0% |  | 14 | 93.3% | 1 | 6.7% |  | 15 | 100.0% | 0 | 0.0% |  | ||||||||||||||||||||
Family history, BC | ||||||||||||||||||||||||||||||||||||||||
 No BC family history | 550 | 85.8% | 91 | 14.2% | 0.719 | 622 | 97.0% | 19 | 3.0% | 0.920 | 590 | 92.0% | 51 | 8.0% | 0.204 | 609 | 95.5% | 32 | 5.0% | 0.891 | ||||||||||||||||||||
 BC family history (+) | 133 | 83.6% | 26 | 16.4% |  | 154 | 96.9% | 5 | 3.0% |  | 145 | 91.2% | 14 | 8.8% |  | 149 | 93.7% | 10 | 6.3% |  | ||||||||||||||||||||
 No data | 66 | 83.5% | 13 | 16.5% |  | 76 | 96.2% | 3 | 3.8% |  | 68 | 86.1% | 11 | 13.9% |  | 75 | 94.9% | 4 | 5.1% |  | ||||||||||||||||||||
Family history, OC | ||||||||||||||||||||||||||||||||||||||||
 No OC family history | 671 | 85.9% | 110 | 14.1% | 0.002 | 758 | 97.1% | 23 | 2.9% | 0.679 | 720 | 92.2% | 61 | 7.8% | 0.011 | 741 | 94.9% | 40 | 5.1% | 0.857 | ||||||||||||||||||||
 OC family history ( +) | 8 | 53.3% | 7 | 46.7% |  | 14 | 93.3% | 1 | 6.7% |  | 11 | 73.3% | 4 | 26.7% |  | 13 | 86.7% | 2 | 13.3% |  | ||||||||||||||||||||
 No data | 70 | 84.3% | 13 | 15.7% |  | 80 | 96.4% | 3 | 3.6% |  | 72 | 86.7% | 11 | 13.3% |  | 79 | 95.2% | 4 | 4.8% |  | ||||||||||||||||||||